Characterisation and impact of reported and unreported exacerbations: Results from ATTAIN

European Respiratory Journal

Volumn 44, Issue 5, 2014, Pages 1156-1165

  Jones, Paul W ^a   Lamarca, Rosa ^b   Chuecos, Ferran ^b   Singh, Dave ^c   Agustí, Alvar ^d,e   Bateman, Eric D ^f   De Miquel, Gonzalo ^b   Caracta, Cynthia ^g   Gil, Esther Garcia ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b R and D Centre ^*  (Spain)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; PLACEBO; BRONCHODILATING AGENT; CORTICOSTEROID; TROPANE DERIVATIVE;

ADULT; ARTICLE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; TREATMENT OUTCOME; TROPANES;

EID: 84921625539     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00038814     Document Type: Article

References (22)

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
2. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
3. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD - A review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009; 4: 203-223.
4. Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: A review. COPD 2010; 7: 214-228.
5. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
6. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21: Suppl. 41, 46s-53s.
7. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S-401S.
8. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic obstructive pulmonary disease Tool (EXACT): A patient-reported outcome (PRO) measure. Value Health 2010; 13: 965-975.
9. Langsetmo L, Platt RW, Ernst P, et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177: 396-401.
10. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
11. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303.
12. Leidy NK, Murray LT, Jones P, et al. Performance of the EXAcerbations of Chronic pulmonary disease Tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11: 316-325.
13. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J 2012; 40: 830-836.
14. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183: 323-329.
15. Jones PW, Chen WH, Wilcox TK, et al. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 2011; 139: 1388-1394.
16. EXACT-PRO Initiative. The Exacerbations of Chronic pulmonary disease Tool (EXACT) User Manual Version 4.0. Bethesda, Evidera, 2013.
17. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593.
18. Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010; 35: 1022-1030.
19. Halpin DM, Laing-Morton T, Spedding S, et al. A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim Care Respir J 2011; 20: 324-331.
20. Calverley P, Pauwels R, Lofdahl CG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 2005; 26: 406-413.
21. Jones PW, Donohue JF, Nedelman J, et al. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: A pooled analysis. Respir Res 2011; 12: 161.
22. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD009285.